Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: DrugBank:EXPT01586 (
G418
)
2,237
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
About 80% of all urological stones are calcium
oxalate
, mainly caused by idiopathic hyperoxaluria (IH). The increased absorption of
oxalate
from the intestine is the major factor underlying IH. The continuous self-renewal of the intestinal epithelium is due to the vigorous proliferation and differentiation of intestinal stem cells. If the intestinal stem cell population can acquire the ability to metabolize calcium
oxalate
by means of oxc and frc transgenes, this will prove a promising new therapy option for IH. In our research, the
oxalate
-degrading genes of Oxalobacter formigenes (Oxf)-the frc gene and oxc gene-were cloned and transfected into a cultured mouse-derived intestinal SC population to give the latter an
oxalate
-degrading function. Oxf was isolated and cultivated and the
oxalate
-degrading genes-frc and oxc-were cloned. The dicistronic eukaryotic expression vector pIRES-oxc-frc was constructed and transferred into the mouse stem cell population. After selection with
G418
, the expression of the genes was identified. The
oxalate
-degrading function of transfected cells was determined by transfection into the intestinal stem cell population of the mouse. The change in
oxalate
concentration was determined with an ion chromatograph. The recombinant plasmid containing oxc and frc genes was transfected into the stem cell population of the mouse and the expression of the genes found normal. The cell population had acquired an
oxalate
-degrading function. The oxc and frc genes could be transfected into the intestinal stem cell population of the mouse and the cells acquired an
oxalate
-degrading function.
...
PMID:The construction of an oxalate-degrading intestinal stem cell population in mice: a potential new treatment option for patients with calcium oxalate calculus. 2189 1